BUZZ-TG Therapeutics rises on new data for autoimmune therapy
Reuters
Feb 06
BUZZ-TG <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on new data for autoimmune therapy
** Shares of biotech firm TG Therapeutics TGTX.O rise 2.7% to $28.51 premarket
** Presented new findings on multiple sclerosis therapy Briumvi for treating a relapsing type of the nerve disorder
** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body
** Updates include real‑world data and studies in children and teens
** Most common side effects were infusion reactions and respiratory infections; serious infections seen in 5% of patients
** Shares ended marginally lower in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.